Liver Transplantation in Patients With Pretransplant Aspergillus Colonization: Is It Safe to Proceed?
Adolescent
Adult
Aged
Aged, 80 and over
Aspergillosis
/ complications
Aspergillus
/ isolation & purification
End Stage Liver Disease
/ complications
Female
Follow-Up Studies
Humans
Liver Transplantation
/ methods
Male
Middle Aged
Preoperative Period
Retrospective Studies
Risk Factors
Severity of Illness Index
Young Adult
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
pubmed:
18
4
2020
medline:
21
7
2021
entrez:
18
4
2020
Statut:
ppublish
Résumé
Patients with end-stage liver disease and pretransplant Aspergillus colonization are problematic for determining liver transplant candidacy and timing of transplantation because of concerns for posttransplant invasive aspergillosis. We performed a retrospective review of the medical and laboratory records of all adult patients (aged ≥18 y) who underwent liver transplantation with pretransplant Aspergillus colonization at the Ronald Reagan University of California, Los Angeles, Medical Center from January 1, 2010, to December 31, 2015. A total of 27 patients who had Aspergillus colonization (respiratory tract 26, biliary tract 1) before liver transplantation were identified. Pretransplant characteristics included previous liver transplant (11 of 27, 40.7%), dialysis (22 of 27, 81.5%), corticosteroid therapy (12 of 27, 44.4%), intensive care unit stay (27 of 27, 100%), and median model for end-stage liver disease score of 39. Only 22.2% (6 of 27) received pretransplant antifungal agents (median duration, 5 d), whereas 100% (27 of 27) received posttransplant antifungal prophylaxis (voriconazole 81.4%, 22 of 27; echinocandin 14.8%, 4 of 27; voriconazole plus echinocandin 3.7%, 1 of 27) for median duration of 85 d. Posttransplant invasive fungal infection occurred in 14.8% (4 of 27; aspergillosis 3, mucormycosis 1). Both 6-month and 12-month survival were 66.7% (18 of 27), but only 1 death was due to fungal infection. Other causes of death were liver graft failure, intraabdominal complications, and malignancy. A substantial number of patients with pretransplant Aspergillus colonization can still undergo successful liver transplantation if they are otherwise suitable candidates and receive appropriate antifungal prophylaxis. Posttransplant outcome in these patients is determined mostly by noninfectious complications and not fungal infection. Pretransplant Aspergillus colonization alone should not necessarily preclude or delay liver transplantation.
Sections du résumé
BACKGROUND
Patients with end-stage liver disease and pretransplant Aspergillus colonization are problematic for determining liver transplant candidacy and timing of transplantation because of concerns for posttransplant invasive aspergillosis.
METHODS
We performed a retrospective review of the medical and laboratory records of all adult patients (aged ≥18 y) who underwent liver transplantation with pretransplant Aspergillus colonization at the Ronald Reagan University of California, Los Angeles, Medical Center from January 1, 2010, to December 31, 2015.
RESULTS
A total of 27 patients who had Aspergillus colonization (respiratory tract 26, biliary tract 1) before liver transplantation were identified. Pretransplant characteristics included previous liver transplant (11 of 27, 40.7%), dialysis (22 of 27, 81.5%), corticosteroid therapy (12 of 27, 44.4%), intensive care unit stay (27 of 27, 100%), and median model for end-stage liver disease score of 39. Only 22.2% (6 of 27) received pretransplant antifungal agents (median duration, 5 d), whereas 100% (27 of 27) received posttransplant antifungal prophylaxis (voriconazole 81.4%, 22 of 27; echinocandin 14.8%, 4 of 27; voriconazole plus echinocandin 3.7%, 1 of 27) for median duration of 85 d. Posttransplant invasive fungal infection occurred in 14.8% (4 of 27; aspergillosis 3, mucormycosis 1). Both 6-month and 12-month survival were 66.7% (18 of 27), but only 1 death was due to fungal infection. Other causes of death were liver graft failure, intraabdominal complications, and malignancy.
CONCLUSIONS
A substantial number of patients with pretransplant Aspergillus colonization can still undergo successful liver transplantation if they are otherwise suitable candidates and receive appropriate antifungal prophylaxis. Posttransplant outcome in these patients is determined mostly by noninfectious complications and not fungal infection. Pretransplant Aspergillus colonization alone should not necessarily preclude or delay liver transplantation.
Identifiants
pubmed: 32301905
pii: 00007890-202103000-00021
doi: 10.1097/TP.0000000000003276
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
586-592Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no funding or conflicts of interest.
Références
Neofytos D, Fishman JA, Horn D, et al. Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transpl Infect Dis. 2010; 12:220–229. doi:10.1111/j.1399-3062.2010.00492.x
doi: 10.1111/j.1399-3062.2010.00492.x
Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev. 2005; 18:44–69. doi:10.1128/CMR.18.1.44-69.2005
doi: 10.1128/CMR.18.1.44-69.2005
Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore). 1999; 78:123–138.
Kusne S, Torre-Cisneros J, Mañez R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992; 166:1379–1383. doi:10.1093/infdis/166.6.1379
doi: 10.1093/infdis/166.6.1379
Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis. 1994; 170:644–652.
Brown RS Jr, Lake JR, Katzman BA, et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation. 1996; 61:666–669. doi:10.1097/00007890-199602270-00029
doi: 10.1097/00007890-199602270-00029
Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver transplantation during 3 decades: analysis of 5347 consecutive liver transplants at a single center. Ann Surg. 2013; 258:409–421. doi:10.1097/SLA.0b013e3182a15db4
doi: 10.1097/SLA.0b013e3182a15db4
De Pauw B, Walsh TJ, Donnelly JP, et al.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008; 46:1813–1821. doi:10.1086/588660
doi: 10.1086/588660
Clinical and Laboratory Standards Institute. M38-A2: Reference Method for Broth Dilution and Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. 2008, 2nd ed. Wayne, PA: Clinical Laboratory Standards Institute
Gitman M, Husain S. Aspergillosis in lung transplant patients: focus on colonization pre-transplant and impact on invasive disease. Curr Fungal Infect Rep. 2014; 8:249–254. doi:10.1007/s12281-014-0207-9
doi: 10.1007/s12281-014-0207-9
Luong ML, Chaparro C, Stephenson A, et al. Pretransplant Aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation. 2014; 97:351–357. doi:10.1097/01.TP.0000437434.42851.d4
doi: 10.1097/01.TP.0000437434.42851.d4
Husain S, Sole A, Alexander BD, et al. The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: executive summary. J Heart Lung Transplant. 2016; 35:261–282. doi:10.1016/j.healun.2016.01.007
doi: 10.1016/j.healun.2016.01.007
Pennington KM, Yost KJ, Escalante P, et al. Antifungal prophylaxis in lung transplant: a survey of United States’ transplant centers. Clin Transplant. 2019; 33:e13630. doi:10.1111/ctr.13630
doi: 10.1111/ctr.13630
Penack O, Tridello G, Hoek J, et al. Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the infectious diseases and acute leukemia working parties. Bone Marrow Transplant. 2016; 51:418–423. doi:10.1038/bmt.2015.237
doi: 10.1038/bmt.2015.237
Maziarz RT, Brazauskas R, Chen M, et al. Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study. Bone Marrow Transplant. 2017; 52:270–278. doi:10.1038/bmt.2016.259
doi: 10.1038/bmt.2016.259
Cordonnier C, Rovira M, Maertens J, et al.; Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica. 2010; 95:1762–1768. doi:10.3324/haematol.2009.020073
doi: 10.3324/haematol.2009.020073
Wingard JR, Carter SL, Walsh TJ, et al.; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010; 116:5111–5118. doi:10.1182/blood-2010-02-268151
doi: 10.1182/blood-2010-02-268151
Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356:335–347. doi:10.1056/NEJMoa061098
doi: 10.1056/NEJMoa061098
Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis. 2004; 39:584–587. doi:10.1086/422723
doi: 10.1086/422723
Sun HY, Cacciarelli TV, Singh N. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2013; 96:573–578. doi:10.1097/TP.0b013e31829d674f
doi: 10.1097/TP.0b013e31829d674f
Pfizer 2019. Label VFend (voriconazole) Tablets, Oral Suspension, for Injection Intravenous. LAB-0271-37.0. 2019, New York, NY: Pfizer
Johnson HJ, Han K, Capitano B, et al. Voriconazole pharmacokinetics in liver transplant recipients. Antimicrob Agents Chemother. 2010; 54:852–859. doi:10.1128/AAC.00429-09
doi: 10.1128/AAC.00429-09
Eschenauer GA, Kwak EJ, Humar A, et al. Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant. 2015; 15:180–189. doi:10.1111/ajt.12993
doi: 10.1111/ajt.12993
Balogh J, Gordon Burroughs S, Boktour M, et al. Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients. Liver Transpl. 2016; 22:163–170. doi:10.1002/lt.24365
doi: 10.1002/lt.24365
Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015; 61:1558–1565. doi:10.1093/cid/civ571
doi: 10.1093/cid/civ571
Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc. 2004; 36:2708–2709. doi:10.1016/j.transproceed.2004.09.043
doi: 10.1016/j.transproceed.2004.09.043
Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006; 12:552–559. doi:10.1016/j.bbmt.2005.12.032
doi: 10.1016/j.bbmt.2005.12.032
Brems JJ, Hiatt JR, Klein AS, et al. Disseminated aspergillosis complicating orthotopic liver transplantation for fulminant hepatic failure refractory to corticosteroid therapy. Transplantation. 1988; 46:479–481. doi:10.1097/00007890-198809000-00038
doi: 10.1097/00007890-198809000-00038
Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis. 1995; 21:1077–1089. quiz 1090. doi:10.1093/clinids/21.5.1077
doi: 10.1093/clinids/21.5.1077
Singh N, Winston DJ, Limaye AP, et al. Performance characteristics of galactomannan and β-d-glucan in high-risk liver transplant recipients. Transplantation. 2015; 99:2543–2550. doi:10.1097/TP.0000000000000763
doi: 10.1097/TP.0000000000000763